20-epi-Vitamin D3 Analogues: A Novel Class of Potent Inhibitors of Proliferation and Inducers of Differentiation of Human Breast Cancer Cell Lines

Cancer Research

Volumn 55, Issue 13, 1995, Pages 2822-2830

  Elstner, Elena ^a   Linker Israeli, Marjane ^a   Said, Johnathan ^a   Umiel, Tehila ^a   de Vos, Sven ^a   Shintaku, I Peter ^a   Heber, David ^a   Binderup, Lise ^b   Uskokovic, Milan ^c   Koeffler, H Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LEO PHARMA A S   (Denmark)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9,10 SECOCHOLESTA 5,7,10(19),16 TETRAEN 23 YNE 1,3,25 TRIOL; 9,10 SECOCHOLESTA 5,7,10(19),16 TETRAENE 1,3,25 TRIOL; CALCITRIOL; CALCITRIOL RECEPTOR; ESTROGEN RECEPTOR; LEXACALCITOL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL DIFFERENTIATION; CELL PROLIFERATION; GROWTH REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

APOPTOSIS; CALCITRIOL; CELL CYCLE; CELL DIFFERENTIATION; CELL NUCLEUS; DNA DAMAGE; GROWTH INHIBITORS; IN VITRO; PROTEIN P53; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, CALCITRIOL; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0028981091     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Manni, A. Hormone receptors. In: I. M. Ariel and J. B. Cleary (eds.). Breast Cancer Diagnosis and Treatment, pp. 119–127. New York: McGraw-Hill Book Co., 1987.
2. McGuire, W. L., Horwitz, K. B., Pearson, O. H., and Segaloff, A. Current status of estrogen and progesterone receptors in breast cancer. Cancer (Phila.), 39: 2934–2947, 1977.
3. Garland, F. C., Garland, C. F., Gorham, E. D., and Young, J. F. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev. Med., 19: 614–622, 1990.
4. Gorham, E. D., Garland, F. C., and Garland, C. F. Sunlight and breast cancer incidence in the USSR. Int. J. Epidemiol., 19: 820–824, 1990.
5. Berger, U., Wilson, P., McClelland, R. A., Colston, K., Haussler, M. R., Pike, J. W., and Coombes, R. C. Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in breast cancer. Cancer Res., 47: 6793–6799, 1987.
6. 3. Clin. Endocrinol., 13: 267–272, 1980.
7. 3 receptors in human skin biopsies. J. Clin. Endocrinol. Metab., 51: 1463–1465, 1980.
8. Colston, K. W., Berger, U., and Coombes, R. C. Possible role for vitamin D in controlling breast cancer cells proliferation. Lancet, 28: 188–191, 1989.
9. Beker, A. R., McDonnell, D. P., Haussler, M. R., Pike, J. W., Shine, J., and O'Malley, B. W. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc. Natl. Acad. Sci. USA, 85: 3294–3298, 1988.
10. 3 receptor in human epithelial cancer cell lines. Cancer Res., 42: 856–859, 1982.
11. Eisman, J. A., Martin, T. J., MacIntyre, I., and Moseley, J. M. 1,25-Dihydroxyvitamin-D receptor in breast cancer cells. Lancet, 2: 1335–1336, 1979.
12. 3 metabolites. Cancer Res., 43: 443–447, 1983.
13. 3. Proc. Natl. Acad. Sci. USA, 76: 4990–4994, 1981.
14. Colston, K. W., Chander, S. K., Mackay, A. G., and Coombes, R. C. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem. Pharmacol., 44: 693–702, 1992.
15. Danielpour, D., Kadomatsu, K., Anzano, M. A., Smith, J. M., and Sporn, M. B. Development and characterization of nontumorigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate. Cancer Res., 54: 3413–3421, 1994.
16. Bower, M., Colston, K. W., Stein, R. C., Hedley, A., Gazet, J-C., Ford, H. T., and Coombes, R. C. Topical calcipotriol treatment in advanced breast cancer. Lancet, 337: 701–702, 1991.
17. 3. Cancer Res., 47: 21–25, 1987.
18. 3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc. Acad. Sci. USA, 80: 201–204, 1983.
19. 3 on metastasis of rat ascites hepatoma K-231. Br. J. Cancer, 50: 123–125, 1984.
20. 3 prolong survival time of leukemic mice. Proc. Natl. Sci. USA, 87: 3929–3932, 1990.
21. 3 on the morphology of human breast cancer cell line BT 20. Differentiation, 40: 63–69, 1989.
22. 3 analogues: a novel class of potent regulators of cell growth and immune responses. Biochem. Pharmacol., 42: 1569–1575, 1991.
23. Mathiasen, I. S., Colston, K. W., and Binderup, L. EB 1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells. J. Steroid Biochem. Mol. Biol., 46: 365–371, 1993.
24. 3: differential effects on leukemic cell growth, differentiation, and intestinal absorption. Cancer Res., 50: 6857–6864, 1990.
25. Mangelsdorf, D. J., Koeffler, H. P., Donaldson, C. A., Pike, J. W., and Haussler, M. R. Induced differentiation in a human promyelocytic leukemia cell line (HL60): receptor-mediated maturation to macrophage-like cells. J. Cell Biol., 98: 391–398, 1984.
26. 3 and its fluorinated analogues. Cancer Res., 44: 5624–5628, 1984.
27. Binderup, L., and Bramm, E. Effects of a novel vitamin D analogue MC 903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem. Pharmacol., 37: 889–895, 1988.
28. 3 analog with potent ability to induce HL-60 cell differentiation without modulating calcium metabolism. Blood, 78: 75–82, 1991.
29. 3 is a potent antileukemic agent with low potential to cause hypercalcemia. Leukemia Res., 18: 453–463, 1994.
30. 3 analogs: effect on leukemic clonal growth and differentiation, and on serum calcium levels 1994. Leukemia Res., 19: 65–72, 1995.
31. 3: an extraordinarily potent inhibitor of leukemic cell growth in vitro. Blood, 84: 1960–1968, 1994.
32. Kiguchi, K., Giometti, C., Chubb, C. H., Fujiki, H., and Huberman, E. Differentiation induction in human breast tumor cells by okadaic acid and related inhibitors of protein phosphatases 1 and 2A. Biochem. Biophys. Res. Commun., 189: 1261–1267, 1992.
33. Sheehan, D. C. Theory and Practice of Histotechnology, Ed. 2, p. 209. St. Louis: C. V. Mosby Co., 1980.
34. Bacus, S. S., Kiguchi, K., Chin, D., King, C. R., and Huberman, E. Differentiation of cultured human breast cancer cells (AU-565 and MCF-7) associated with loss of cell surface HER-2/neu antigen. Mol. Carcinog., 3: 350–362, 1990.
35. Martin, S. J., and Cotter, T. G. Apoptosis of human leukemia: induction, morphology, and molecular mechanisms. In: Apoptosis II: Molecular Basis of Apoptosis in Disease, p. 1. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1994.
36. Sellins, K. S., and Cohen, J. J. Gene induction by γ-irradiation leads to DNA fragmentation in lymphocytes. J. Immunol., 139: 3199–3206, 1987.
37. Said, J. W., Pinkus, G. S., Lones, M. A., Preston, M., and Shintaku, I. P. Expression of bcl-2 oncogene protein in malignant lymphomas, including Hodgkin's disease and non-Hodgkin's lymphomas of T-cell phenotype. Appl. Immunohistochem., 1: 108–114, 1993.
38. Lones, M. A., Said, J. W., and Pinkus, G. S. Bcl-2 oncogene protein in preferentially expressed in Reed-Sternberg cells in Hodgkin's disease of modular sclerosis subtype. Am J. Clin Pathol., 102: 464–467, 1994.
39. Walts, A. E., Said, J. W., and Koeffler, H. P. Is immunoreactivity for p53 useful in distinguishing benign from malignant effusions? Localisation of p53 gene product in benign mesothelial and adenocarcinoma cells. Modern Pathol., 7: 462–46J8, 1994.
40. Banks, L., Matlashewski, G., and Crawford, L. Isolation of human p53 specific monoclonal antibodies and their use in the studies of human p53 expression. Eur. J. Biochem., 159: 529–534, 1986.
41. Bartek, J., Iggo, R., Gannon, J., and Lane, D. P. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene, 5: 893–899, 1990.
42. Miller, C. W., Chumakov, A., Said, J., Chen, D. L., Aslo, A., and Koeffler, H. P. Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription. Oncogene, 8: 1815–1824, 1993.
43. Ceriani, R. L., Peterson, J. A., Blank, E. W., Chan, C. M., and Cailleau, R. Development and characterization of breast carcinoma cell lines as in vitro and in vivo models for breast cancer diagnosis and therapy. In Vitro Cell Dev. Biol., 28: 397–400, 1992.
44. Casey, G., Lo-Hsueh, M., Lopez, M. E., Vogelstein, B., and Stanbridge, E. J. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene, 6: 1791–1797, 1991.
45. Midland, M. M., Plumet, Y., and Okamura, W. H. Effect of C20 stereochemistry on the conformational profile of the side chains of vitamin D analogs. Bioorg. Med. Chem. Lett., 3: 1799–1804, 1993.
46. 3 (VD) analogs MC903, EB1089 and KH1060 activate the VD receptor: homodimers show higher ligand sensitivity than heterodimers with retinoid X receptors, J. Steroid Biochem. Mol. Biol., 51: 137–142, 1994.
47. 3 are associated with enhanced activation of the vitamin D receptor. J. Biol. Chem., 270: 3–8, 1995.
48. 3 analog structure-function assessment of the rapid stimulation of intestinal calcium absorption (transcaltachia). J. Bone Miner. Res., 7: 457–463, 1992.
49. 3 receptor. Mol. Cell Endocrinol., 70: 1–11, 1990.
50. 3. Arch. Biochem. Biophys., 268: 35–39,1989.
51. 3 in breast cancer cells occur at the estrogen response element level but through differen molecular mechanisms. Cancer Res., 54: 1458–1464,1994.
52. Collins, S. J., Ruscetti, F. W., Gallagher, R. E., and Gallo, R. C. Normal functional characteristics of cultured human promyelocytic leukemia cells (HL-60) after induction of differentiation by dimethylsulfoxide. J. Exp. Med., 149: 969–977, 1979.
53. Douer, D., and Koeffler, H. P. Inhibition of the clonal growth of human myeloid leukemia cells. J. Clin. Invest., 69: 277–283, 1982.
54. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539–542, 1994.
55. Raff, M. C. Social control on cell survival and cell death. Nature (Lond.), 356: 397–400, 1992.
56. Oltval, Z. N., and Korsmeyer, S. J. Checkpoints of dueling dimers foil death wishes. Cell, 79: 189–192, 1994.
57. Vaux,, D. L., Cory, S., and Adams, J. M. bcl-2 gene promotes hemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature (Lond.), 335: 440–442, 1988.
58. Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R. D., and Korsmeyer, S. J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (Lond.), 348: 334–339, 1990.
59. Hockenbery, D. M. The bcl-2 oncogene and apoptosis. Semin. Immunol., 4:413–420, 1992.
60. McDonnell, T. J., Deane, N., Piatt, F. M., Nuñez, G., Jaeger, U., McKearn, J. P., and Korsmeyer, S. J. Bcl-2 immunoglobin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell, 57: 79–88, 1989.
61. El-Deiry, W. S., Tokino, T, Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Un, D., Mercer, W. E., Kinzler, W. E., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817–825, 1993.
62. Herper, J. W., Adam, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. The p21 cdk-interacting protein Cip 1 is a potent inhibitor of Gl cyclin-dependent kinases. Cell, 75: 805–816, 1993.
63. Symonds, H., Krall, L., Remington, L., Saenz-Robles, L., Lowe, S., Jacks, T., and Van Dyke, T. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell, 78: 703–711, 1994.
64. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature (Lond.), 352: 345–347, 1991.
65. Show, P., Bovey, R., Tardy, S., Sahli, R., Sordat, B., and Costa, J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad. Sci. USA, 89: 4495–4499, 1992.
66. Crawford, L. V., Pim, D. C., And Lamb, P. The cellular protein p53 in human tumours. Mol. Biol. Med., 2: 261–272, 1984.
67. Cattorctti, G., Rilke, F., Andreo1α, S., D'Amato, L., and Domenico, D. p53 in breast cancer. Int. J. Cancer, 41: 178–183, 1988.
68. Riou, G., Lé M. G., Travagli, J. P., Moll, U. M., and Levine, A. J. Poor prognosis of p53 nuclear overexpression and mutation in inflammatory breast carcinoma. Proc. Am. Assoc. Cancer Res., 35: 220, 1994.
69. Mehta, R. R., Graves, J. M., and Das Gupta, T. K. p53 levels and breast tumor metastasis in experimental animals. Proc. Am. Assoc. Cancer Res., 35: 48, 1994.
70. Moll, U. M., Riou, G., and Levine, J. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA, 89: 7262–7266, 1992.
71. Ryan, J. J., and Clarke, M. F. Alteration of p53 conformation and induction of apoptosis in a murine erythroleukemia cell line by dimethylsulfoxide. Leukemia Res., 75: 617–621, 1994.